Breaking News Instant updates and real-time market news.

TIME

Time Inc.

, HRB

H&R Block

09:14
11/28/16
11/28
09:14
11/28/16
09:14

On The Fly: Pre-market Movers

HIGHER: Time Inc. (TIME), up 11.6% after The New York Post reported that the former CEO of Warner Music Group, Edgar Bronfman Jr., recently submitted a bid to buy the company for $18 a share which company's board is said to have rejected... Recro Pharma (REPH), up 14% after announcing that the second of two Phase 3 clinical trials evaluating intravenous meloxicam for the treatment of acute postoperative pain achieved its primary endpoint... Cognizant Technology (CTSH), up 10% after Elliott Management, which owns more than 4% of the common stock and equivalents of Cognizant, made public a "value-enhancement plan" that it contends can help the company achieve a value of $80-$90+ per share by the end of 2017. LOWER: H&R Block (HRB), down 3% after the stock was downgraded to Sell from Neutral at BTIG... Tupperware Brands (TUP), down 3% after being downgraded to Sell from Neutral at B. Riley... Hasbro (HAS), down 1% following a downgrade to Neutral from Overweight at Piper Jaffray.

TIME

Time Inc.

HRB

H&R Block

TUP

Tupperware Brands

HAS

Hasbro

$87.94

1.05 (1.21%)

REPH

Recro Pharma

$7.76

-0.23 (-2.88%)

CTSH

Cognizant

$53.25

1.39 (2.68%)

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

  • 07

    Dec

TIME Time Inc.

05/19/16
05/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo analyst Craig Bijou upgraded Mazor Robotics (MZOR) to Outperform, saying the stock has more appreciation potential after yesterday's rally on its commercial agreement with Medtronic (MDT). The partnership "provides a strong endorsement" of Mazor's next-generation technology, Bijou told investors. 2. Macquarie upgraded Time Inc. (TIME) to Outperform from Neutral, as the firm's analyst believes Time will see a dramatic turnaround in earnings and cash flow beginning in the second half of this year following heavy cost cutting and investments in content. 3. RBC Capital analyst Robert Stallard upgraded L-3 Communications (LLL) to Outperform and increased his price target to $150 from $137. Following management meetings, the analyst has increased confidence L-3 is on track to achieve its long-term operating margin goals and improved execution. 4. Halliburton (HAL) upgraded to Buy from Neutral at Griffen Securities. 5. Credit Suisse (CS) upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/19/16
05/19/16
UPGRADE

Outperform
Time Inc. upgraded to Outperform at Macquarie
As previously reported, Macquarie upgraded Time Inc to Outperform from Neutral. The firm's analyst believes Time will see a dramatic turnaround in earnings and cash flow beginning in the second half of this year following heavy cost cutting and investments in content.
05/19/16
MACQ
05/19/16
UPGRADE
MACQ
Outperform
Time Inc. upgraded to Outperform from Neutral at Macquarie
05/17/16
05/17/16
INITIATION

Time Inc. to host investor open house
Investor open house to be held in New York on May 17 at 9 am. Webcast Link
HRB H&R Block

11/28/16
BTIG
11/28/16
DOWNGRADE
BTIG
Sell
H&R Block downgraded to Sell from Neutral at BTIG
11/28/16
BTIG
11/28/16
DOWNGRADE
BTIG
Sell
H&R Block downgraded on Trump outlook at BTIG
As noted earlier, BTIG downgraded H&R Block to Sell from Neutral. Analyst Mark Palmer notes that President-elect Trump has said he wants to put H&R Block out of business by simplifying the tax code. Palmer thinks that the chances of this vision becoming reality has increased significantly. Target $18.
11/16/16
11/16/16
DOWNGRADE
Target $25

Equal Weight
H&R Block downgraded on election risk at Morgan Stanley
As previously reported, Morgan Stanley downgraded H&R Blobk to Equal Weight from Overweight and lowered its price target to $25 from $26. Analyst Thomas Allen views the election results as a negative as it increases the risk of a simplified tax code and the potential repeal of ACA removes an industry tailwind. Allen also sees risk to margins from Refund Advances as the benefits seem to have diminished and are more commonplace.
11/16/16
MSCO
11/16/16
DOWNGRADE
MSCO
Equal Weight
H&R Block downgraded to Equal Weight from Overweight at Morgan Stanley
TUP Tupperware Brands

01/28/16
01/28/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Azure Midstream Partners (AZUR) downgraded at Stifel... Chesapeake (CHK) downgraded to Hold from Buy at Wunderlich... CorEnergy (CORR) downgraded at Stifel... DCP Midstream (DPM) downgraded to Hold from Buy at Stifel... DynCorp (DCP) downgraded at Stifel... Ericsson (ERIC) downgraded on challenging outlook at BMO Capital... H&E Equipment (HEES) downgraded to Neutral from Buy at UBS... Halcon Resources (HK) downgraded to Hold from Buy at Wunderlich... InvenSense (INVN) downgraded to Market Perform from Outperform at Barrington... Invitae (NVTA) downgraded to Market Perform from Outperform at Leerink... Kirby (KEX) downgraded to Sector Perform from Outperform at RBC Capital... MEG Energy (MEGEF) downgraded to Equal Weight from Overweight at Barclays... Metro (MTTRY) downgraded to Underweight from Neutral at JPMorgan... OSI Systems (OSIS) downgraded to Hold following Q2 miss at BB&T... Oasis Petroleum (OAS) downgraded to Hold from Buy at Wunderlich... Pan American Silver (PAAS) downgraded to Market Perform from Outperform at FBR Capital... Qualcomm (QCOM) downgraded to Market Perform from Outperform at William Blair... Range Resources (RRC) downgraded to Equal Weight from Overweight at Barclays... Rockwell Automation (ROK) downgraded to Underperform from Market Perform at Bernstein... Royal Gold (RGLD) downgraded to Market Perform from Outperform at FBR Capital... SEI Investments (SEIC) downgraded to Underperform at Keefe Bruyette... SandRidge Energy (SD) downgraded to Sell from Hold at Wunderlich... Seadrill (SDRL) downgraded to Equal Weight from Overweight at Morgan Stanley... ServiceNow (NOW) downgraded to Neutral from Buy at MKM Partners... State Bank Financial (STBZ) downgraded to Hold from Buy at Sandler O'Neill... Sunoco Logistics (SXL) downgraded at Stifel... Tallgrass Energy GP (TEGP) downgraded to Hold from Buy at Stifel... Tallgrass Energy (TEP) downgraded to Hold from Buy at Stifel... Textron (TXT) downgraded to Hold from Buy at Drexel Hamilton... TripAdvisor (TRIP) downgraded to Underperform from Market Perform at Raymond James... Tupperware Brands (TUP) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Steel (X) downgraded to Hold from Buy at Argus... United Rentals (URI) downgraded to Neutral from Buy at UBS... Welltower (HCN) downgraded to Hold from Buy at Evercore ISI... Western Gas Partners (WES) downgraded to Hold from Buy at Stifel... Whiting Petroleum (WLL) downgraded to Hold from Buy at Wunderlich.
02/24/16
KEYB
02/24/16
NO CHANGE
KEYB
Overweight
Tupperware filing delay not about accounting issues, says KeyBanc
KeyBanc said it believes Tupperware's 10-K filing delay is not due to accounting issues and they think the 10K will be filed within the next 15 days. The firm has an Overweight rating on Tupperware shares.
02/26/16
KEYB
02/26/16
DOWNGRADE
KEYB
Sector Weight
Tupperware Brands downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Jason Gere downgraded Tupperware Brands to Sector Weight saying he sees little upside to the low end of the company's fiscal year organic sales guidance. Gere does not find the stock's risk/reward attractive over the next 12 months.
11/28/16
RILY
11/28/16
DOWNGRADE
Target $47
RILY
Sell
Tupperware Brands downgraded to Sell from Neutral at B. Riley
B. Riley analyst Linda Bolton Weiser downgraded Tupperware Brands to Sell saying the stock has not moved lower to reflect post-election currency devaluations. The analyst sees a worsening currency backdrop and poor fundamentals. She cut her price target for Tupperware shares to $47 from $64.
HAS Hasbro
$87.94

1.05 (1.21%)

07/19/16
PIPR
07/19/16
UPGRADE
Target $88
PIPR
Overweight
Hasbro upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Stephanie Wissink upgraded Hasbro to Overweight saying the recent pullback in shares provides an opportunity to buy for "holiday 2016 and full year 2017 drivers." Momentum should return to Hasbro business, led by girls and games in the second half of 2016, Wissink tells investors in a research note. The analyst keeps an $88 price target for the shares.
11/28/16
PIPR
11/28/16
DOWNGRADE
Target $88
PIPR
Neutral
Hasbro downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Stephanie Wissink downgraded Hasbro to Neutral saying the shares are fairly valued at current levels. It's best to pause and revisit in early 2017, Wissink tells investors in a research note. She keeps an $88 price target for the shares.
05/10/16
05/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wayfair (W) downgraded to Neutral at Citi by analyst Mark May, who said international investments and aggressive hiring are likely to limit EBITDA upside in 2016. 2. SolarCity (SCTY) downgraded to Neutral at BofA/Merrill by analyst Krish Sankar, who said the company's strategy to manage growth and costs, and long-term economic value creation has become increasingly unclear. He also said the cost strategy will be impacted by numerous factors including the policy environment, financing and execution risks. The company was also downgraded to Market Perform at Avondale. 3. Hasbro (HAS) downgraded to Neutral at Piper Jaffray with analyst Stephanie Wissink citing limited upside to her unchanged price target of $88. 4. Nike (NKE) resumed with a Market Perform at Wells Fargo by analyst Tom Nikic, who said the company's near-term financials "may prove to be fairly noisy" due to the upcoming Summer Olympics in Brazil. The analyst adds that Nike is facing a level of competition that it has not experienced in quite some time. 5. Sprouts Farmers Markets (SFM) downgraded to Sell at Goldman with analyst Stephen Grambling saying both thee consensus estimates and the valuation are overly optimistic. He said that increasing competition caused the company's comp growth to stall. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/16
07/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Outperform from Underperform at CLSA with analyst Jeremy Scott saying the Chiptopia loyalty program is a highly compelling and engaging platform that re-energized its most loyal customers while providing a large-scale acquisition of customer data. 2. Hasbro (HAS) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stephanie Wissink saying the recent pullback in shares provides an opportunity to buy for "holiday 2016 and full year 2017 drivers." 3. IDEX Corp. (IEX) upgraded to Buy from Neutral at Janney Capital with analyst Michael Gaugler saying the company's commentary that North American industrial end markets are showing signs of stabilization was probably more relevant than the second quarter results. 4. Ethan Allen (ETH) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Cristina Fernandez saying Ethan Allen has renewed sales momentum and sees several initiatives in the next few quarters that could sustain sales and drive shares higher. 5. Tesoro (TSO) upgraded to Buy from Neutral at Citi with analyst Faisel Khan saying the shares are trading at a significant discount to net asset value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
REPH Recro Pharma
$7.76

-0.23 (-2.88%)

10/03/16
BMUR
10/03/16
INITIATION
Target $21
BMUR
Buy
Recro Pharma coverage assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage on Recro Pharma with a Buy rating citing upcoming catalysts and its lead product candidate which could serve as a non-opioid alternative for pain management. Yang placed a $21 price target on Recro Pharma shares, which is reduced from the firm's prior price target of $28.
09/16/16
ROTH
09/16/16
INITIATION
Target $24
ROTH
Buy
Recro Pharma initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Recro Pharma with a Buy rating and $24 price target.
08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
08/29/16
JANY
08/29/16
INITIATION
JANY
Buy
Recro Pharma initiated with a Buy at Janney Capital
Target $21.
CTSH Cognizant
$53.25

1.39 (2.68%)

10/31/16
KEYB
10/31/16
NO CHANGE
KEYB
Cognizant should report upbeat earnings, says KeyBanc
KeyBanc says that Cognizant can increase investor confidence by "clarifying the impact from potential FCPA violations and President Gordon Coburn's abrupt departure." The firm thinks that the company's negative comments and lowered guidance are priced into the stock at current levels. It believes that the set-up for the company heading into its Q3 results is positive. The firm reiterates a $67 price target and an Overweight rating on the shares.
11/23/16
WBLR
11/23/16
DOWNGRADE
WBLR
Market Perform
Cognizant downgraded to Market Perform from Outperform at William Blair
William Blair analyst Anil Doradla downgraded Cognizant Technology Solutions to Market Perform.
11/23/16
WBLR
11/23/16
DOWNGRADE
WBLR
Market Perform
Cognizant downgraded to Market Perform from Outperform at William Blair
William Blair analyst Anil Doradla downgraded Cognizant Technology Solutions to Market Perform from Outperform. After visiting India, the analyst is concerned that Cognizant will be affected by structural changes within the services industry. The newest headwind to the industry is related to the potential policy changes under President-elect Trump, Doradla tells investors in a research note. Further, the analyst is disappointed by the company's lack of capital returns to shareholders. He also expects Cognizant's growth will continue decelerating from 2016 through 2018. In pre-market trading, the shares are down 53c to $52.65.
11/22/16
BOFA
11/22/16
DOWNGRADE
BOFA
Underperform
Cognizant downgraded two notches to Underperform at BofA/Merrill
BofA/Merrill analyst David Ridley-Lane downgraded Cognizant two notches to Underperform from Buy and lowered its price target to $48 from $66. The analyst sees risks from potential immigration reform under a Trump administration and a slower growth profile. Further, Ridley-Lane said revenue growth at Cognizant's largest customers has stalled and views a reacceleration of growth in 2017 as unlikely.

TODAY'S FREE FLY STORIES

SEAS

SeaWorld

$15.65

-0.16 (-1.01%)

20:01
06/25/17
06/25
20:01
06/25/17
20:01
Hot Stocks
SeaWorld receives subpoenas, forms special committee over 'Blackfish' statements »

SeaWorld stated in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

19:57
06/25/17
06/25
19:57
06/25/17
19:57
Periodicals
Facebook plans to offer TV-quality content by late summer, WSJ says »

Facebook is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FRO

Frontline

$5.59

0.08 (1.45%)

, GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

19:50
06/25/17
06/25
19:50
06/25/17
19:50
Periodicals
Frontline abandons plans to buy Gener8, WSJ says »

Frontline (FRO) has…

FRO

Frontline

$5.59

0.08 (1.45%)

GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$84.83

0.4 (0.47%)

18:46
06/25/17
06/25
18:46
06/25/17
18:46
Hot Stocks
Third Point confirms $3.5B stake in Nestle, urges change at company »

In a letter published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.84

-0.68 (-0.90%)

18:23
06/25/17
06/25
18:23
06/25/17
18:23
Periodicals
Wal-Mart initially clamped down on alcohol, swearing at Jet.com, WSJ says »

After Wal-Mart acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

17:55
06/25/17
06/25
17:55
06/25/17
17:55
Periodicals
EU plans EUR1B fine against Google this week, FT reports »

The EU plans to levy a…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NSRGY

Nestle

$84.83

0.4 (0.47%)

17:37
06/25/17
06/25
17:37
06/25/17
17:37
Periodicals
Dan Loeb's Third Point targets Nestle, Bloomberg says »

Nestle is being targeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$47.62

0.34 (0.72%)

17:27
06/25/17
06/25
17:27
06/25/17
17:27
Hot Stocks
Cheniere Energy announces commencement of Korea Gas LNG contract »

Cheniere Energy and Korea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.